Unani treatment for leucorrhoea due to bacterial vaginosis

Effect of Gulnar (Punica granatum Linn) suppository in leucorrhoea due to bacterial vaginosis- A randomized controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/052712

Enrollment

Registered

2023-05-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N899- Noninflammatory disorder of vagina, unspecified

Interventions

Intervention1: Gulnar (Punica granatum Linn): In the test group placebo will be prescribed orally thrice a day and Gulnar 3g suppository will be given vaginally at bedtime for 7 days Control Intervent

Eligibility

Inclusion criteria

Inclusion criteria: Married woman with offensive vaginal discharge, pruritus vulvae, pelvic pain and positive Amsel criteria and Nugent score

Exclusion criteria

Exclusion criteria: Patients with Uncontrolled systemic diseases, malignancy, pelvic pathology, trichomoniasis, candidiasis, gonorrhoea and other types of vaginitis History of previous antibiotic therapy OCPs and IUCD Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Improvement in Nugent scoreTimepoint: 7 days	—

Secondary

Measure	Time frame
Improvement in Amsel criteriaTimepoint: 7 days	—

Countries

India

Contacts

Public ContactProf Ismath Shameem

National Institute of Unani Medicine

dr.ismaths@gmail.com9538274583

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026